US2004042978A1PendingUtilityA1
Method and composition for the treatment of epidermal irritations and infections
Priority: Jun 9, 1998Filed: Mar 31, 2003Published: Mar 4, 2004
Est. expiryJun 9, 2018(expired)· nominal 20-yr term from priority
Inventors:William J. Embro
A61P 31/04A61P 31/10A61P 31/02A61P 31/22A61K 8/19A61K 8/44A61K 8/27A61K 2800/75A61K 8/21A61K 8/365A61Q 19/00A61P 17/00A61K 8/36A61Q 17/00A61K 8/20
44
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
An improved stannous fluoride composition is disclosed. The composition comprises stannous fluoride and at least one zinc containing compound. The zinc containing compounds stabilized and prevent hydrolysis of the stannous ions resulting in a more effective stannous fluoride composition for use in the treatment of epidermal irritations and infections.
Claims
exact text as granted — not AI-modifiedI claim:
1 . A composition comprising stannous fluoride and at least one zinc containing compound.
2 . A composition according to claim 1 wherein the zinc containing compound is a zinc carboxylate.
3 . A composition according to claim 2 wherein the zinc carboxylate is selected from the group consisting of zinc gluconate, zinc tartrate, zinc malate, zinc citrate and zinc acetate.
4 . A composition according to claim 2 wherein the zinc carboxylate is zinc gluconate.
5 . A composition according to claim 2 wherein the zinc containing compound further includes a zinc salt.
6 . A composition according to claim 5 wherein the zinc salt is selected from the group consisting of zinc chloride, zinc sulfate, zinc phosphate, zinc oxide, zinc pyrophosphate and zinc thiocynate.
7 . A composition according to claim 5 wherein the zinc salt is zinc chloride.
8 . A composition according to claim 1 comprising stannous fluoride and zinc gluconate in a non-aqueous medium.
9 . A composition according to claim 1 further comprising at least one amino acid.
10 . A composition according to claim 9 wherein the amino acid is an essential or non-essential L or D amino acids from the group consisting of lysine, arginine, histidine, phenylalanine, threonine, leucine, isoluceine, cysteine, methionine, valine, alanine, glycine, proline, glutamine, serine, tryptophan, tyrosine, and asparagine.
11 . A composition according to claim 1 wherein the stannous fluoride is in an amount from about 0.01% to about 10.0% by weight.
12 . A composition according to claim 2 wherein the zinc carboxylate is in an amount from about 0.05% to about 10.0% by weight.
13 . A composition according to claim 5 wherein zinc salt is in an amount from about 0.05% to about 10.0% by weight.
14 . A composition according to claim 9 wherein the amino acid is in an amount of from about 0.05% to about 50.0% by weight.
15 . A composition according to claim 9 wherein the amino acid is L-Lysine.
16 . A composition according to claim 1 comprising:
Stannous fluoride
0.20% by wt;
Zinc gluconate
1.50% by wt; and
Glycerin
98.30% by wt.
17 . A composition according to claim 5 comprising:
Stannous fluoride
0.20 % by wt;
Zinc gluconate
1.50% by wt;
Zinc chloride
0.50% by wt;
Glycerin
85.50% by xvt; and
Carbopol
7.30% by wt.
18 . A composition according to claim 5 comprising:
Stannous fluoride
0.20% by wt;
Zinc gluconate
1.50% by wt;
Zinc chloride
0.50% by wt;
L-Lysine
10.00% by wt;
Glycerine
60.00% by wt;
Carbopol
2.00% by wt; and
Distilled Water
24.80% by wt.
19 . A method of treating an epidermal irritation or infection comprising administering an effective amount of a composition comprising stannous fluoride and at least one zinc containing compound to an animal in need thereof.
20 . A method according to claim 19 wherein the infection is a viral, bacterial, parasitic or fungal infection.
21 . A method according to claim 20 wherein the viral infection is a herpes infection.
22 . A method according to claim 20 wherein the viral infection is papilloma virus.
23 . A method according to claim 20 wherein the fungal infection is caused by the genera Microsporum or Trichophyton.
24 . A method according to claim 20 wherein the bacterial infection is a caused by Staphylococcus bacterial, Streptococcus or Dermatophilis.
25 . A method according to claim 19 wherein the epidermal irritation is a burn.
26 . A method according to claim 20 wherein the animal is a human.
27 . A method according to claim 20 wherein the animal is a horse, cat or dog.Join the waitlist — get patent alerts
Track US2004042978A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.